Development of novel agents based on nitric oxide for the control of colon cancer

Acta Pharmacologica Sinica

Volumn 28, Issue 9, 2007, Pages 1429-1433

  Kozoni, Vassiliki ^a   Rosenberg, Theophilos ^b   Rigas, Basil ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

Chemoprevention; Colon cancer; Nitric oxide; Nitric oxide aspirin; Nitric oxide donating NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID 3 (NITROXYMETHYL)PHENYL ESTER; FLUOROURACIL; IBUPROFEN; INDOMETACIN; NCX 4040; NCX 530; NITRIC OXIDE DONOR; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; SULINDAC; UNCLASSIFIED DRUG;

CANCER PREVENTION; COLON CANCER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; NONHUMAN; OXIDATIVE STRESS; REVIEW; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; COLONIC NEOPLASMS; HUMANS; NITRIC OXIDE; NITRIC OXIDE DONORS;

EID: 34548412564     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1111/j.1745-7254.2007.00696.x     Document Type: Review

References (29)

1. Author X. Statistics for 2006. City of publication : American Cancer Society 2006.
2. Ignarro LJ. Nitric oxide as a unique signaling molecule in the vascular system: a historical overview. J Physiol Pharmacol 2002 53 : 503 14.
3. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007 87 : 315 424.
4. Rao CV. Nitric oxide signaling in colon cancer chemoprevention. Mutat Res 2004 555 : 107 19.
5. Hirst D, Robson T. Targeting nitric oxide for cancer therapy. J Pharm Pharmacol 2007 59 : 3 13.
6. Ying L, Hofseth LJ. An emerging role for endothelial nitric oxide synthase in chronic inflammation and cancer. Cancer Res 2007 67 : 1407 10.
7. Roberts J II., Morrow J. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment gout. In : Hardman JG, Limbird LE, editors. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. New York : McGraw-Hill 2001. p 687 31.
8. Tashjian AH Jr., Voelkel EF, Goldhaber P, Levine L. Successful treatment of hypercalcemia by indomethacin in mice bearing a prostaglan-din-producing fibrosarcoma. Prostaglandins 1973 3 : 515 24.
9. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002 94 : 252 66.
10. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003 348 : 891 9.
11. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003 348 : 883 90.
12. Shiff SJ, Qiao L, Tsai LL, Rigas B. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995 96 : 491 503.
13. Shiff SJ, Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs) [comment]. J Exp Med 1999 190 : 445 50.
14. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, et al. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996 52 : 237 45.
15. Rayyan Y, Williams J, Rigas B. The role of NSAIDs in the prevention of colon cancer. Cancer Invest 2002 20 : 1002 11.
16. del Soldato P, Sorrentino R, Pinto A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 20 : 319 23.
17. Kashfi K, Borgo S, Williams JL, Chen J, Gao J, Glekas A, et al. Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo. J Pharmacol Exp Ther 2005 312 : 978 88.
18. Williams JL, Borgo S, Hasan I, Castillo E, Traganos F, Rigas B. Nitric oxide-releasing nonsteroidal anti-inflammatory drugs (NSAIDs) alter the kinetics of human colon cancer cell lines more effectively than traditional NSAIDs: implications for colon cancer chemoprevention. Cancer Res 2001 61 : 3285 9.
19. Ouyang N, Williams JL, Rigas B. NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR) {delta} expression in APCmin/+ mice proportionally to their tumor inhibitory effect: Implications for the role of PPAR{delta} in carcinogenesis. Carcinogenesis 2006 27 : 232 9.
20. Gao J, Liu X, Rigas B. Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxi-dative stress. Proc Natl Acad Sci USA 2005 102 : 17207 12.
21. Bak AW, McKnight W, Li P, Del Soldato P, Calignano A, Cirino G, et al. Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci 1998 62 : L367 73.
22. Williams JL, Kashfi K, Ouyang N, del Soldato P, Kopelovich L, Rigas B. NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice. Biochem Biophys Res Commun 2004 313 : 784 8.
23. Rao CV, Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, et al. Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther 2006 5 : 1530 8.
24. Leonetti C, Scarsella M, Zupi G, Zoli W, Amadori D, Medri L. Efficacy of a nitric oxide-releasing nonsteroidal anti-inflammatory drug and cytotoxic drugs in human colon cancer cell lines in vitro and xenografts. Mol Cancer Ther 2006 5 : 919 26.
25. Fiorucci S, Santucci L, Gresele P, Faccino RM, Del Soldato P, Morelli A. Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study. Gastroenterology 2003 124 : 600 7.
26. Iconomou G, Kalofonos HP, Koutras AK, Vagenakis AG, Rigas B. Pilot study of nitric oxide-donating aspirin in patients with pancreatic cancer pain. J Support Oncol 2006 4 : 168.
27. Rigas B, Kashfi K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol Med 2004 10 : 324 30.
28. Williams JL, Nath N, Chen J, Hundley TR, Gao J, Kopelovich L, et al. Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemoprevention. Cancer Res 2003 63 : 7613 8.
29. Gao J, Kashfi K, Liu X, Rigas B. NO-donating aspirin induces phase II enzymes in vitro and in vivo. Carcinogenesis 2006 27 : 803 10.